ANIXA BIOSCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-07-31 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-04-30 was $0.00.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-01-31 was $60.00K.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-10-31 was $103.00K, a 25.36% decline year-over-year.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $105.00K, a 76.97% decline from fiscal 2024.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $456.00K, a 29.18% increase from fiscal 2023.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $353.00K, a 19.59% decline from fiscal 2022.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $439.00K, a 1.15% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-09 | $163.00K derived: sum of 4 quarters · filed 2026-09-09 |
| 2026-04-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-06-10 | $165.00K derived: sum of 4 quarters · filed 2026-09-09 |
| 2026-01-31 | $60.00K 10-Q · filed 2026-03-09 | |
| 2025-10-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-12 | $105.00K 10-K · filed 2026-01-12 |
| 2025-07-31 | $2.00K 10-Q · filed 2026-09-09 | |
| 2024-10-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-12 | $456.00K 10-K · filed 2026-01-12 |
| 2024-07-31 | $194.00K 10-Q · filed 2025-09-10 | $590.00K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | $57.00K 10-Q · filed 2025-05-28 | $399.00K derived: sum of 4 quarters · filed 2025-05-28 |
| 2024-01-31 | $67.00K 10-Q · filed 2025-03-11 | $417.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-10-31 | $272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-10 | $353.00K 10-K · filed 2025-01-10 |
| 2023-07-31 | $3.00K 10-Q · filed 2024-09-06 | -$310.00K derived: sum of 4 quarters · filed 2024-09-06 |
| 2023-04-30 | $75.00K 10-Q · filed 2024-06-04 | $517.00K derived: sum of 4 quarters · filed 2024-06-04 |
| 2023-01-31 | $3.00K 10-Q · filed 2024-03-12 | |
| 2022-10-31 | -$391.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-01-16 | $439.00K 10-K · filed 2024-01-16 |
| 2022-07-31 | $830.00K 10-Q · filed 2023-09-06 | |
| 2021-10-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | $434.00K 10-K · filed 2023-01-04 |
| 2021-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-09-09 | $294.00K derived: sum of 4 quarters · filed 2022-09-09 |
| 2021-04-30 | $190.00K 10-Q · filed 2022-06-10 | $312.54K derived: sum of 4 quarters · filed 2022-06-10 |
| 2021-01-31 | $104.00K 10-Q · filed 2022-03-11 | $197.79K derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-04 | $122.27K 10-K · filed 2022-01-04 |
| 2020-07-31 | $18.54K 10-Q · filed 2021-09-01 | $141.84K derived: sum of 4 quarters · filed 2021-09-01 |
| 2020-04-30 | $75.25K 10-Q · filed 2021-06-10 | $146.00K derived: sum of 4 quarters · filed 2021-06-10 |
| 2020-01-31 | $28.48K 10-Q · filed 2021-03-11 | $127.85K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-10-31 | $19.57K derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07 | $122.07K 10-K · filed 2021-01-07 |
| 2019-07-31 | $22.70K 10-Q · filed 2020-09-08 | |
| 2019-04-30 | $57.10K 10-Q · filed 2020-06-09 | |
| 2019-01-31 | $22.70K 10-Q · filed 2020-03-09 | |
| 2018-10-31 | $58.14K 10-K · filed 2020-01-09 | |
| 2017-10-31 | $1.61K derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $7.27K 10-K · filed 2019-01-11 |
| 2017-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-09-08 | $15.87K derived: sum of 4 quarters · filed 2018-01-09 |
| 2017-04-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-26 | $21.02K derived: sum of 4 quarters · filed 2018-01-09 |
| 2017-01-31 | $5.67K 10-Q · filed 2017-03-16 | |
| 2016-10-31 | $10.20K derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-09 | $33.58K 10-K · filed 2018-01-09 |
| 2016-07-31 | $5.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-19 | |
| 2015-10-31 | $10.30K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-08 | $44.63K 10-K · filed 2016-12-08 |
| 2014-10-31 | $24.65K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23 | $75.88K 10-K · filed 2015-12-23 |
| 2014-07-31 | $50.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-09-15 | |
| 2013-10-31 | $25.61K 10-K · filed 2015-01-29 | |
| 2012-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29 | $208.45K 10-K · filed 2013-01-29 |
| 2012-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-09-14 | $393.70K derived: sum of 4 quarters · filed 2013-01-29 |
| 2012-04-30 | $61.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-06-14 | |
| 2012-01-31 | $147.25K 10-Q · filed 2012-03-16 | |
| 2011-10-31 | $185.25K derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-01-29 | $1.28M 10-K · filed 2013-01-29 |
| 2010-10-31 | $1.25M 10-K · filed 2012-01-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |